关注
Koji Izutsu
Koji Izutsu
在 ncc.go.jp 的电子邮件经过验证
标题
引用次数
引用次数
年份
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma
M Sakata-Yanagimoto, T Enami, K Yoshida, Y Shiraishi, R Ishii, Y Miyake, ...
Nature genetics 46 (2), 171-175, 2014
7192014
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study …
M Yamaguchi, YL Kwong, WS Kim, Y Maeda, C Hashimoto, C Suh, ...
Journal of clinical oncology 29 (33), 4410-4416, 2011
6882011
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
K Kataoka, Y Shiraishi, Y Takeda, S Sakata, M Matsumoto, S Nagano, ...
Nature 534 (7607), 402-406, 2016
6772016
Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma
H Tilly, F Morschhauser, LH Sehn, JW Friedberg, M Trněný, JP Sharman, ...
New England Journal of Medicine 386 (4), 351-363, 2022
5052022
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed …
M Kamdar, SR Solomon, J Arnason, PB Johnston, B Glass, V Bachanova, ...
The Lancet 399 (10343), 2294-2308, 2022
4892022
AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma
JP Leonard, M Trneny, K Izutsu, NH Fowler, X Hong, J Zhu, H Zhang, ...
Journal of clinical oncology 37 (14), 1188-1199, 2019
3992019
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study
SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ...
The Lancet Oncology 22 (10), 1403-1415, 2021
3862021
Phase I study of dexamethasone, methotrexate, ifosfamide, l‐asparaginase, and etoposide (SMILE) chemotherapy for advanced‐stage, relapsed or refractory …
M Yamaguchi, R Suzuki, YL Kwong, WS Kim, Y Hasegawa, K Izutsu, ...
Cancer science 99 (5), 1016-1020, 2008
3052008
The corepressor CtBP interacts with Evi-1 to repress transforming growth factor β signaling
K Izutsu, M Kurokawa, Y Imai, K Maki, K Mitani, H Hirai
Blood, The Journal of the American Society of Hematology 97 (9), 2815-2822, 2001
2962001
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ...
The Lancet Haematology 6 (9), e448-e458, 2019
2202019
Prospective measurement of Epstein-Barr virus–DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type
R Suzuki, M Yamaguchi, K Izutsu, G Yamamoto, K Takada, Y Harabuchi, ...
Blood, The Journal of the American Society of Hematology 118 (23), 6018-6022, 2011
2182011
ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma
GS Nowakowski, A Chiappella, RD Gascoyne, DW Scott, Q Zhang, ...
Journal of Clinical Oncology 39 (12), 1317-1328, 2021
2102021
Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis
Y Imai, M Kurokawa, K Izutsu, A Hangaishi, K Takeuchi, K Maki, S Ogawa, ...
Blood, The Journal of the American Society of Hematology 96 (9), 3154-3160, 2000
2032000
Gain‐of‐function mutations and copy number increases of Notch2 in diffuse large B‐cell lymphoma
S Lee, K Kumano, K Nakazaki, M Sanada, A Matsumoto, G Yamamoto, ...
Cancer science 100 (5), 920-926, 2009
1852009
Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese …
D Ennishi, Y Maeda, N Niitsu, M Kojima, K Izutsu, J Takizawa, ...
Blood, The Journal of the American Society of Hematology 116 (24), 5119-5125, 2010
1682010
The evi‐1 oncoprotein inhibits c‐Jun N‐terminal kinase and prevents stress‐induced cell death
M Kurokawa, K Mitani, T Yamagata, T Takahashi, K Izutsu, S Ogawa, ...
The EMBO journal, 2000
1572000
Long-term survival following autologous and allogeneic stem cell transplantation for blastic plasmacytoid dendritic cell neoplasm
T Aoki, R Suzuki, Y Kuwatsuka, S Kako, K Fujimoto, J Taguchi, T Kondo, ...
Blood, The Journal of the American Society of Hematology 125 (23), 3559-3562, 2015
1542015
FDG-PET in T-cell and NK-cell neoplasms
S Kako, K Izutsu, Y Ota, Y Minatani, M Sugaya, T Momose, K Ohtomo, ...
Annals of oncology 18 (10), 1685-1690, 2007
1522007
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
JS Abramson, SR Solomon, J Arnason, PB Johnston, B Glass, ...
Blood 141 (14), 1675-1684, 2023
1432023
Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma
A Masuda, K Nakamura, K Izutsu, K Igarashi, R Ohkawa, M Jona, ...
British journal of haematology 143 (1), 60-70, 2008
1382008
系统目前无法执行此操作,请稍后再试。
文章 1–20